

Estimate change	
TP change	
Rating change	

Bloomberg	ATLP IN
Equity Shares (m)	29
M.Cap.(INRb)/(USDb)	171.5 / 1.9
52-Week Range (INR)	7793 / 4752
1, 6, 12 Rel. Per (%)	0/-12/-22
12M Avg Val (INR M)	382
Free float (%)	54.8

Financials and Valuations (INR b)

Y/E March	FY26E	FY27E	FY28E
Sales	62.5	69.6	77.4
EBITDA	10.9	12.3	14.0
PAT	7.0	7.7	8.8
EPS (INR)	237.0	262.4	299.4
EPS Gr. (%)	40.0	10.7	14.1
BV/Sh.(INR)	2,091	2,314	2,570

Ratios

Net D:E	-0.0	-0.0	-0.1
RoE (%)	11.9	11.9	12.3
RoCE (%)	11.0	11.3	11.7
Payout (%)	14.8	14.8	14.8

Valuations

P/E (x)	24.7	22.3	19.6
P/BV (x)	2.8	2.5	2.3
EV/EBITDA (x)	15.7	13.8	12.0
Div. Yield (%)	0.6	0.7	0.8
FCF Yield (%)	2.3	1.8	2.3

Shareholding pattern (%)

As On	Dec-25	Sep-25	Dec-24
Promoter	45.2	45.2	45.2
DII	25.4	25.0	22.8
FII	7.5	8.3	11.2
Others	21.9	21.5	20.8

FII Includes depository receipts

CMP: INR5,827 TP: INR7,500 (+29%) Buy

Growth momentum sustains with the performance segment at the core

- Atul (ATLP) reported in-line revenue of INR15.7b (+11% YoY) in 3QFY26. Revenue from the Performance & Other Chemicals segment increased 11% YoY, while the Life Science Chemicals segment's revenue rose 9% YoY. EBITDA grew 29% YoY to INR2.9b and Adj. PAT increased 74% YoY to INR2b.
- We increase our FY26/FY27/FY28 earnings estimates by 9%/5%/11% on the back of better-than-expected earnings in 3QFY26—with EBITDA margins beating our estimates, higher other income, and lower interest cost.
- The stock is trading at ~22.3x/19.6x FY27E/FY28E EPS of INR262.4/INR299.4 and ~13.8x/12x FY27E/FY28E EV/EBITDA. We value the stock at 25x FY28E EPS to arrive at our TP of INR7,500. Reiterate BUY.

EBITDA in line; Adj. PAT beats our estimates due to higher other income and lower tax

- ATLP's revenue was INR15.7b (+11% YoY). Life Science Chemicals' revenue stood at INR4.5b (+9% YoY), while Performance Chemicals' revenue was INR11.5b (+11% YoY) during the quarter.
- Gross margin stood at 47.5% (vs. 50.5% in 3QFY25), and EBITDA margin expanded 250bp YoY to 18.3%. Life Science Chemicals' EBIT margin stood at 23% (flat YoY), while EBIT stood at INR1b. Performance Chemicals' EBIT margin stood at 7.6% (+40bp YoY), and EBIT came in at INR879m.
- Consolidated EBITDA grew 29% YoY to INR2.9b (in line with our est.), and Adj. PAT grew 68% YoY to INR2b (est. INR1.6b) (adjusted for the impact of New Labor Code of INR413.5m).
- In 9MFY26, consolidated revenue/EBITDA/adj. PAT grew ~11%/15%/39% to INR46b/INR7.9b/INR5.1b.
- The Life Science segment recorded revenue/EBIT growth of ~8%/10% YoY to INR13.4b/INR2.7b and EBIT margin expansion of ~40bp YoY to 20.4% in 9MFY26. The Performance segment recorded revenue/EBIT growth of ~12%/12% YoY to INR33.7b/INR2.9b, and EBIT margin remained flat YoY at 8.7% in 9M.

Valuation and view

- We expect ATLP to continue its healthy momentum, led by: 1) capacity expansion for its key products, 2) new projects, 3) debottlenecking its existing capacities, 4) capturing a higher market share, and 5) expanding its international presence.
- The stock is trading at ~22.3x/19.6x FY27E/FY28E EPS of INR262.4/INR299.4 and ~13.8x/12x FY27E/FY28E EV/EBITDA. We increase our FY26/FY27/FY28 earnings estimates by 9%/5%/11% on the back of better-than-expected earnings in 3QFY26—with EBITDA margins beating our estimates, higher other income, and lower interest cost. We value the stock at ~25x FY28E EPS to arrive at our TP of INR7,500.

Consolidated - Quarterly Snapshot
(INR m)

Y/E March	FY25				FY26				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
Gross Sales	13,221	13,928	14,168	14,516	14,780	15,519	15,736	16,465	55,834	62,500
YoY Change (%)	11.8	16.7	24.5	19.8	11.8	11.4	11.1	13.4	18.1	11.9
Total Expenditure	10,988	11,501	11,928	12,287	12,425	12,844	12,852	13,439	46,704	51,560
Gross Margin (%)	50.0%	53.1%	50.5%	49.7%	48.7%	46.6%	47.5%	50.0%	50.8%	48.2%
EBITDA	2,232	2,427	2,241	2,229	2,355	2,675	2,884	3,026	9,130	10,940
Margin (%)	16.9	17.4	15.8	15.4	15.9	17.2	18.3	18.4	16.4	17.5
Depreciation	766	775	810	817	820	810	798	830	3,168	3,258
Interest	54	89	43	54	45	49	37	35	240	166
Other Income	130	315	158	487	262	485	386	379	1,090	1,512
PBT before EO expense	1,543	1,878	1,546	1,845	1,752	2,301	2,435	2,540	6,812	9,027
Extra-Ord expense	0	0	0	0	0	0	413	0	0	413
PBT	1,543	1,878	1,546	1,845	1,752	2,301	2,022	2,540	6,812	8,614
Tax	455	514	407	560	447	489	399	762	1,937	2,097
Rate (%)	29.5	27.4	26.4	30.3	25.5	21.3	19.8	30.0	28.4	24.3
MI and Profit/Loss of Asso. Cos.	33	31	33	16	19	12	13	17	113	61
Reported PAT	1,121	1,395	1,171	1,301	1,324	1,824	1,636	1,795	4,988	6,578
Adj PAT	1,121	1,395	1,171	1,301	1,324	1,824	2,041	1,795	4,988	6,983
YoY change (%)	9.8	52.9	62.5	121.3	18.1	30.7	74.3	38.0	53.9	40.0
Margin (%)	8.5	10.0	8.3	9.0	9.0	11.8	13.0	10.9	8.9	11.2
Segmental Revenue (INR mn)										
Life Science Chemicals	4,236	4,078	4,164	4,439	4,492	4,400	4,543	4,972	16,917	12,680
Performance & Other chemicals	9,386	10,237	10,412	10,547	10,669	11,451	11,554	12,024	40,582	31,196
Others	194	186	187	171	164	263	187	223	739	545
Segmental EBIT (INR mn)										
Life Science Chemicals	710	836	956	966	684	1,009	1,047	-	3,468	2,758
Performance & Other chemicals	852	990	752	855	1,000	1,038	879	-	3,449	2,597
Others	50	27	34	12	23	65	18	0	123	73
Segmental EBIT Margin (%)										
Life Science Chemicals	16.8%	20.5%	23.0%	21.8%	15.2%	22.9%	23.0%	0.0%	20.5%	21.7%
Performance & Other chemicals	9.1%	9.7%	7.2%	8.1%	9.4%	9.1%	7.6%	0.0%	8.5%	8.3%
Others	25.9%	14.3%	18.1%	7.1%	14.3%	24.6%	9.4%	0.0%	16.6%	13.3%

Exhibit 1: Revised estimates

Earnings change (INR m)	New			Old			Change		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	62,500	69,645	77,415	63,212	70,748	78,634	-1%	-2%	-2%
EBITDA	10,940	12,328	13,964	10,644	12,084	13,450	3%	2%	4%
Adj. PAT	6,983	7,729	8,820	6,387	7,380	7,975	9%	5%	11%
Adj. EPS (INR)	237.0	262.4	299.4	216.8	250.5	270.7	9%	5%	11%

ATLP's 3QFY26 in charts

Exhibit 1: Sales increased 11% YoY




Exhibit 2: Margins trend




Exhibit 3: EBITDA increased 29% YoY




Exhibit 4: PAT was up 10% YoY




Exhibit 5: Life Science's revenue increased 9% YoY...




Exhibit 6: ...while EBIT margin remained flat YoY








Exhibit 7: Performance segment's revenue rose 11% YoY...

Exhibit 8: ...and EBIT margin expanded 40bp YoY

Exhibit 9: Performance and Other Chemicals' contribution to the overall revenue mix stood at 71%, while it was 28% for the Life Science Chemicals segment

Exhibit 10: EBIT mix for the Performance & Other Chemicals segment stood at 45%, while the same stood at 54% for the Life Science Chemicals segment


Financial story in charts

Exhibit 11: Expect ~12% revenue CAGR over FY25-28...




Exhibit 12: ...with exports increasing to ~48%




Exhibit 13: Expect EBITDAM to recover to 18% in FY28





Exhibit 14: ...with PAT margin expanding to 11%



Financials and valuations

Consolidated - Income Statement								(INR m)
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Total Income from Operations	37,315	50,809	54,275	47,257	55,834	62,500	69,645	77,415
Change (%)	-8.8	36.2	6.8	-12.9	18.1	11.9	11.4	11.2
Raw Materials	16,952	25,886	28,640	25,105	27,456	32,364	35,867	39,482
Employees Cost	3,104	3,425	3,702	3,980	4,546	4,920	5,461	6,062
Other Expenses	8,088	12,383	14,185	11,804	14,702	14,275	15,988	17,907
Total Expenditure	28,144	41,695	46,527	40,890	46,704	51,560	57,317	63,451
Gross Margin (%)	54.6	49.1	47.2	46.9	50.8	48.2	48.5	49.0
EBITDA	9,171	9,114	7,749	6,367	9,130	10,940	12,328	13,964
Margin (%)	24.6	17.9	14.3	13.5	16.4	17.5	17.7	18.0
Depreciation	1,363	1,767	1,978	2,429	3,168	3,258	3,521	3,805
EBIT	7,808	7,348	5,770	3,938	5,961	7,681	8,807	10,160
Int. and Finance Charges	94	92	79	111	240	166	160	155
Other Income	1,030	760	1,149	582	1,090	1,512	1,600	1,700
PBT bef. EO Exp.	8,744	8,016	6,840	4,409	6,812	9,027	10,247	11,705
EO Items	0	0	0	0	0	413	0	0
PBT after EO Exp.	8,744	8,016	6,840	4,409	6,812	8,614	10,247	11,705
Total Tax	2,217	2,050	1,812	1,265	1,937	2,097	2,579	2,946
Tax Rate (%)	25.3	25.6	26.5	28.7	28.4	24.3	25.2	25.2
Minority Interest	73	82	38	97	113	61	61	61
Reported PAT	6,600	6,047	5,066	3,241	4,988	6,578	7,729	8,820
Adjusted PAT	6,600	6,047	5,066	3,241	4,988	6,983	7,729	8,820
Change (%)	-1.6	-8.4	-16.2	-36.0	53.9	40.0	10.7	14.1
Margin (%)	17.7	11.9	9.3	6.9	8.9	11.2	11.1	11.4
Consolidated - Balance Sheet								(INR m)
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	296	296	295	295	295	295	295	295
Total Reserves	37,969	43,994	46,419	50,849	55,691	61,298	67,886	75,404
Net Worth	38,265	44,290	46,714	51,143	55,986	61,592	68,181	75,698
Total Loans	1,017	1,384	470	2,319	1,977	988	791	1,028
Deferred Tax Liabilities	1,351	1,436	1,338	1,742	2,253	2,253	2,253	2,253
Capital Employed	40,940	47,418	49,002	55,694	60,854	65,472	71,863	79,618
Gross Block	19,874	23,835	27,228	39,871	43,587	47,587	51,587	55,587
Less: Accum. Deprn.	6,309	8,076	10,054	12,483	15,651	18,909	22,430	26,234
Net Fixed Assets	13,566	15,760	17,174	27,388	27,936	28,677	29,157	29,352
Goodwill on Consolidation	291	291	291	291	291	291	291	291
Capital WIP	2,497	4,205	10,329	2,808	1,243	1,243	1,243	1,243
Total Investments	13,643	13,419	8,842	13,953	17,692	17,692	17,692	17,692
Curr. Assets, Loans, and Adv.	19,375	23,389	21,045	20,322	22,848	27,615	34,675	43,483
Inventory	5,941	8,641	7,894	6,183	7,293	8,562	9,540	12,302
Account Receivables	7,332	9,890	8,446	9,270	11,263	12,842	14,311	16,756
Cash and Bank Balance	3,482	689	520	723	647	2,130	3,859	6,685
Loans and Advances	2,619	4,169	4,185	4,146	3,646	4,081	6,964	7,742
Curr. Liability and Prov.	8,432	9,645	8,678	9,069	9,156	10,047	11,195	12,444
Account Payables	5,631	6,347	5,385	5,793	6,147	6,678	7,442	8,272
Other Current Liabilities	2,170	2,538	2,760	2,754	2,431	2,721	3,032	3,371
Provisions	631	760	533	522	578	647	721	802
Net Current Assets	10,943	13,744	12,367	11,254	13,692	17,569	23,480	31,039
Appl. of Funds	40,939	47,419	49,002	55,694	60,854	65,472	71,863	79,618

Financials and valuations

Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Basic (INR)								
EPS	222.9	204.2	171.6	110.0	169.3	237.0	262.4	299.4
EPS Growth (%)	-1.6	-8.4	-16.0	-35.9	53.9	40.0	10.7	14.1
Cash EPS	268.9	263.9	238.6	192.5	276.9	347.7	381.9	428.5
BV/Share	1,292	1,496	1,582	1,736	1,900	2,091	2,314	2,570
DPS	19.9	24.9	24.9	20.0	25.0	33.0	38.7	44.2
Payout (%)	8.9	12.2	14.5	18.2	14.8	14.8	14.8	14.8
Valuation (x)								
P/E	26.3	28.7	34.2	53.3	34.6	24.7	22.3	19.6
Cash P/E	21.8	22.2	24.6	30.4	21.2	16.9	15.3	13.7
P/BV	4.5	3.9	3.7	3.4	3.1	2.8	2.5	2.3
EV/Sales	4.6	3.4	3.2	3.7	3.1	2.7	2.4	2.2
EV/EBITDA	18.7	19.1	22.3	27.4	19.1	15.7	13.8	12.0
Dividend Yield (%)	0.3	0.4	0.4	0.3	0.4	0.6	0.7	0.8
FCF per share	133.9	-121.3	-56.6	55.7	113.5	134.5	107.5	135.2
Return Ratios (%)								
RoE	18.9	14.7	11.1	6.6	9.3	11.9	11.9	12.3
RoCE	17.7	13.7	10.5	6.2	8.7	11.0	11.3	11.7
RoIC	29.5	21.7	14.5	8.3	10.7	13.6	14.1	14.8
Working Capital Ratios								
Fixed Asset Turnover (x)	2.8	3.5	3.3	2.1	2.0	2.2	2.4	2.6
Asset Turnover (x)	0.9	1.1	1.1	0.8	0.9	1.0	1.0	1.0
Inventory (Days)	58	62	53	48	48	50	50	58
Debtor (Days)	72	71	57	72	74	75	75	79
Creditor (Days)	55	46	36	45	40	39	39	39
Leverage Ratio (x)								
Current Ratio	2.3	2.4	2.4	2.2	2.5	2.7	3.1	3.5
Net Debt/Equity ratio	-0.1	0.0	0.0	0.0	0.0	0.0	0.0	-0.1

Consolidated - Cash Flow Statement

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
(INR m)								
OP/(Loss) before Tax	8,817	8,097	6,878	4,506	6,925	9,027	10,247	11,705
Depreciation	1,363	1,767	1,978	2,429	3,168	3,258	3,521	3,805
Interest Expenses	94	92	79	111	240	166	160	155
Others	-826	-580	-206	-408	-705	0	0	0
Direct Taxes Paid	-2,023	-2,017	-1,934	-1,073	-1,506	-2,097	-2,579	-2,946
(Inc.)/Dec. in WC	-245	-5,046	271	1,110	-2,090	-2,393	-4,182	-4,734
CF from Operations	7,180	2,314	7,067	6,675	6,031	7,962	7,167	7,984
(Inc.)/Dec. in FA	-3,215	-5,905	-8,739	-5,035	-2,687	-4,000	-4,000	-4,000
Free Cash Flow	3,964	-3,591	-1,672	1,640	3,344	3,962	3,167	3,984
Change in Investments	-3,899	4,136	3,572	-2,000	-2,677	0	0	0
Others	651	93	474	203	413	0	0	0
CF from Investments	-6,464	-1,676	-4,694	-6,832	-4,951	-4,000	-4,000	-4,000
Inc.-(Dec.) in Debt	182	117	-914	1,849	-342	-988	-198	237
Interest Paid	-87	-99	-79	-116	-237	-166	-160	-155
Dividend Paid	-617	-590	-1,828	-1,356	-589	-971	-1,141	-1,302
Others	0	-3	246	-1	-11	61	61	61
CF from Fin. Activity	-522	-575	-2,575	375	-1,178	-2,065	-1,438	-1,159
Inc./Dec. in Cash	194	63	-202	219	-98	1,897	1,730	2,825
Opening Balance	261	469	577	380	603	513	1,997	3,726
Closing Balance	469	577	380	603	513	1,997	3,726	6,552

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may: (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 2011129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).

6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.